Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 162 of 162 entries
View as:

Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05547399 Org: User:
Start: 06/07/22 End: 12/07/22 Due: 12/07/23

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05909904 Org: User:
Start: 07/21/23 End: 01/31/27 Due: 01/31/28

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

Phase: N/A Priority: Normal
NCT ID: NCT03575065 Org: User:
Start: 06/22/18 End: 04/14/21 Due: 04/14/22

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Phase: N/A Priority: Normal
NCT ID: NCT04470908 Org: User:
Start: 07/29/20 End: 11/10/20 Due: 11/10/21

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04669262 Org: User:
Start: 12/09/20 End: 05/21/21 Due: 05/21/22

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02610361 Org: User:
Start: 11/20/13 End: 10/31/17 Due: 10/31/18

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03333915 Org: User:
Start: 12/21/16 End: 08/11/21 Due: 08/11/22

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Phase: N/A Priority: Normal
NCT ID: NCT04948697 Org: User:
Start: 08/20/21 End: 02/01/24 Due: 02/01/25

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase: N/A Priority: Normal
NCT ID: NCT04068519 Org: User:
Start: 12/28/16 End: 05/31/20 Due: 05/31/21

A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03561298 Org: User:
Start: 06/07/18 End: 07/02/18 Due: 07/02/19

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03209973 Org: User:
Start: 04/21/17 End: 11/02/20 Due: 11/02/21

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05644626 Org: User:
Start: 03/31/24 End: 08/31/25 Due: 08/31/26